Free shipping on all orders over $ 500

Ceralasertib(AZD6738)

Cat. No. M8914
Ceralasertib(AZD6738) Structure
Size Price Availability Quantity
5mg USD 120  USD120 In stock
10mg USD 200  USD200 In stock
25mg USD 440  USD440 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. AZD6738 induces cell death and senescence in non-small cell lung cancer (NSCLC) cell lines. AZD6738 impairs viability of four Kras mutant cell lines: H23, H460, A549, and H358, with the lowest GI50 and greatest maximal inhibition in H460 and H23 cells (1.05 μM, 88.0% and 2.38 μM, 86.2%, respectively). AZD6738 potentiates the cytotoxicity of cisplatin and gemcitabine in NSCLC cell lines with intact ATM kinase signaling, and potently synergizes with cisplatin in ATM-deficient NSCLC cells.

In vivo: In nude mice bearing H460 and H23 tumors, AZD6738 (50 mg/kg, p.o.) results in tumor growth inhibition (TGI), and the the combination with cisplatin causes rapid regression of ATM-deficient H23 tumors. In nude mice bearing LoVo xenografts, a combination of AZD6738 (50 mg/kg) + IR (2 Gy) avoids toxicity while still maintaining efficacy.

Customer Product Validations & Biological Datas
Source Oncotarget (2015 Dec). Figure 5. AZD6738
Method Western blot
Cell Lines H460 and A549 cells
Concentrations 0.3 or 1.0 μM
Incubation Time 48 hour
Results In H460 shATM cells, 1.0 μM AZD6738 shifted cisplatin IC50 from 2.77 μM to 0.22 μM (12.59-fold), compared to 2.36 μM to 0.43 μM (5.44-fold) and 1.83 uM to 0.84 (2.18-fold) in wildtype and scrambled control cells, respectively. Similar results were seen in A549 shATM cells. Treatment with 1.0 μM AZD6738 reduced cisplatin IC50 from 19.84 μM to 1.02 μM (19.45-fold) versus reductions from 7.79 μM to 2.61 μM (2.98-fold) and 9.68 μM to 3.48 μM (2.78- fold) in wildtype and scrambled control cells, respectively. Treatment with 0.3 μM AZD6738 also resulted in greater shifts in cisplatin IC50 and lower net IC50 values in shATM cell lines compared to wildtype and scrambled control lines.
Source Sci Rep (2015 Aug). Figure 6. AZD6738
Method multi-parametric cell based assays
Cell Lines LoVo cells
Concentrations 80 mg/kg
Incubation Time 3 weeks
Results From tumor volume simulations an efficacious starting dose of 80 mg/kg AZD6738 was identified, providing clinicians with an indication of the expected rate of tumor regression and recovery.
Protocol
Cell Experiment
Cell lines H23, H460, A549, and H358 cells
Preparation method Cells are treated in white walled, clear bottom 96-well plates with the indicated doses of AZD6738, cisplatin, gemcitabine, or combination for 48 h. ATP levels are assessed as surrogate measure of viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay and Safire2 plate reader. Raw data are corrected for background luminescence prior to further analysis. For AZD6738 treatment, log dose response curves are generated in GraphPad Prism 6 by nonlinear regression (log(inhibitor) vs. response with variable slope) of log-transformed (x = log(x)) data normalized to the mean of untreated controls. GI50 values, defined as the dose X at which Y = 50%, were extrapolated from dose response curves.
Concentrations ~30 μM
Incubation time 48 h
Animal Experiment
Animal models Female athymic nude mice bearing H23 or H460 xenografts
Formulation 10% DMSO, 40% propylene glycol, and 50% sterile dH2O
Dosages 25 or 50 mg/kg
Administration p.o.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 412.51
Formula C20H24N6O2S
CAS Number 1352226-88-0
Purity 99.26%
Solubility DMSO: 70 mg/mL
Ethanol: 40 mg/mL warmed
Storage at -20°C
References

[1] Kim HJ, et al. Int J Cancer. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.

[2] Vendetti FP, et al. Oncotarget. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.

[3] Kwok M, et al. Lancet. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway.

[4] Checkley S, et al. Sci Rep. Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738.

Related ATM/ATR Products
AZ32

AZ32 is an orally bioavailable and blood-brain barrier-(BBB)penetrating inhibitor of ATM with IC50 of <6.2 nM and 0.31 μM for ATM enzyme in cell.

AZD0156

AZD0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities.

AZD1390

AZD1390 is a potent and selective inhibitor of ATM in cells (IC50 = 0.78 nM) with the ability to cross the blood-brain barrier.

AZ31

AZ31 is a potent and highly selective ATM inhibitor.

BAY-1895344

Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Ceralasertib(AZD6738) supplier, ATM/ATR, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.